Literature DB >> 33768065

Neurofibromatosis Type 1 with Highly Active Relapsing-Remitting Multiple Sclerosis (RRMS).

Silvia Ciotti1, Antonella Cometa2, Claudia De Carlo3, Giancarlo Martini4, Andrea Marona5, Laura Filippetti1, Diego Carducci6, Silvano Baratta1, Mauro Zampolini6, Francesco Corea1.   

Abstract

Neurofibromatosis type 1 (NF1) is an autosomal dominant neurocutaneous disease which confers an increased risk of malignant tumour development. Relapsing remitting multiple sclerosis (RRMS) is an inflammatory demyelinating disease of the central nervous system. The coexistence of multiple sclerosis and NF1 is rare but has been reported. Here, we describe the case of a 31-year-old man with NF1 and subacute walking problems with proximal pain in the lower limbs who was successfully treated with natalizumab. LEARNING POINTS: The coexistence of multiple sclerosis (MS) and neurofibromatosis type 1 (NF1) is very rare but has been described in the literature.Follow-up of patients with NF1 is important as the early detection and management of MS can prevent further disability.Appropriate treatment and physical therapy can improve the patient's activity and social life. © EFIM 2021.

Entities:  

Keywords:  Multiple sclerosis; case report; natalizumab; neurofibromatosis 1; neurorehabilitation

Year:  2021        PMID: 33768065      PMCID: PMC7977044          DOI: 10.12890/2021_002190

Source DB:  PubMed          Journal:  Eur J Case Rep Intern Med        ISSN: 2284-2594


  6 in total

Review 1.  Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.

Authors:  Alan J Thompson; Brenda L Banwell; Frederik Barkhof; William M Carroll; Timothy Coetzee; Giancarlo Comi; Jorge Correale; Franz Fazekas; Massimo Filippi; Mark S Freedman; Kazuo Fujihara; Steven L Galetta; Hans Peter Hartung; Ludwig Kappos; Fred D Lublin; Ruth Ann Marrie; Aaron E Miller; David H Miller; Xavier Montalban; Ellen M Mowry; Per Soelberg Sorensen; Mar Tintoré; Anthony L Traboulsee; Maria Trojano; Bernard M J Uitdehaag; Sandra Vukusic; Emmanuelle Waubant; Brian G Weinshenker; Stephen C Reingold; Jeffrey A Cohen
Journal:  Lancet Neurol       Date:  2017-12-21       Impact factor: 44.182

2.  Primary progressive multiple sclerosis and neurofibromatosis type 1.

Authors:  Piotr Iwanowski; Marta Kowalska; Michał Prendecki; Jolanta Dorszewska; Wojciech Kozubski; Małgorzata Rydzanicz; Rafał Płoski; Jacek Losy
Journal:  Mult Scler Relat Disord       Date:  2019-04-25       Impact factor: 4.339

3.  The range of multiple sclerosis associated with neurofibromatosis type 1.

Authors:  P Perini; P Gallo
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-11       Impact factor: 10.154

4.  Multiple sclerosis and neurofibromatosis type 1: report of seven patients from Iran.

Authors:  M Etemadifar; F Fatehi; M A Sahraian; A Borhanihaghighi; P M Ardestani; M Kaji-Esfahani; A H Maghzi
Journal:  Mult Scler       Date:  2009-09       Impact factor: 6.312

5.  Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis.

Authors:  Pietro Iaffaldano; Giuseppe Lucisano; Carlo Pozzilli; Vincenzo Brescia Morra; Angelo Ghezzi; Enrico Millefiorini; Francesco Patti; Alessandra Lugaresi; Giovanni Bosco Zimatore; Maria Giovanna Marrosu; Maria Pia Amato; Antonio Bertolotto; Roberto Bergamaschi; Franco Granella; Gabriella Coniglio; Gioacchino Tedeschi; Patrizia Sola; Giacomo Lus; Maria Teresa Ferrò; Gerardo Iuliano; Francesco Corea; Alessandra Protti; Paola Cavalla; Angelica Guareschi; Mariaemma Rodegher; Damiano Paolicelli; Carla Tortorella; Vito Lepore; Luca Prosperini; Francesco Saccà; Damiano Baroncini; Giancarlo Comi; Maria Trojano
Journal:  Brain       Date:  2015-09-11       Impact factor: 13.501

6.  Neurofibromatosis I and multiple sclerosis.

Authors:  Christina Bergqvist; François Hemery; Salah Ferkal; Pierre Wolkenstein
Journal:  Orphanet J Rare Dis       Date:  2020-07-14       Impact factor: 4.123

  6 in total
  1 in total

1.  Primary Progressive Multiple Sclerosis in a Portuguese Patient With Neurofibromatosis Type 1.

Authors:  Inês Carvalho; Miguel Quintas-Neves; Joana Pinto; Ana Filipa Santos; João Pereira
Journal:  Cureus       Date:  2021-12-21
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.